NCT05176951View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
Pulmonary Hypertension
Interventions
DRUG

Treprostinil Palmitil

Oral inhalation using a capsule-based dry powder inhaler device.

DRUG

Placebo

Oral inhalation using a capsule-based dry powder inhaler device.

Trial Locations (25)

2050

AUS003, Camperdown

2109

AUS005, Macquarie Park

4000

BEL002, Liège

13125

GER002, Berlin

14050

GER012, Berlin

15706

ESP009, Santiago de Compostela

20123

ITA004, Milan

20900

ITA002, Monza

33011

ESP007, Oviedo

35010

ESP006, Las Palmas de Gran Canaria

35392

GER010, Giessen

45239

GER003, Essen

69126

GER006, Heidelberg

80131

ITA003, Napoli

81377

GER004, Munich

90127

ITA001, Palermo

C1280AEB

ARG003, Barracas

S2013KDS

ARG001, Rosario

CI094AAD

ARG008, Buenos Aires

01307

GER001, Dresden

07120

ESP003, Palma de Mallorca

08035

ESP010, Barcelona

08907

ESP005, Barcelona

G81 4HX

GBR003, Glasgow

S10 2JF

GBR001, Sheffield

All Listed Sponsors
lead

Insmed Incorporated

INDUSTRY